Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Classical hematology 1

Conditions

Ovarian Neoplasms 86Breast Neoplasms 68Triple Negative Breast Neoplasms 32Prostatic Neoplasms 32Fallopian Tube Neoplasms 25Neoplasms 23Neoplasm Metastasis 21Pancreatic Neoplasms 18Endometrial Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

olaparib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fanconi Anemia, Complementation Group N × olaparib × Clear all
NCT04038502 2025-08-20

COBRA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡